All In Biotech

Drug Trial Radar · NCT03938636

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

116

Actual

Start

Apr 8, 2019

Primary completion

Feb 8, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Navidea BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial will look at scans of the hands and wrists taken from healthy control subjects (HCs) and from subjects with rheumatoid arthritis (RA). Before each scan, subjects will be given an injection of Tc 99m tilmanocept to help the scan identify inflammation in the hand and wrist joints, which can be a part of the RA disease. Data from the scans will be used to calculate a number referred to as tilmanocept uptake value (or TUV) that is a measure of how much Tc 99m tilmanocept has located in the joints. The questions this trial aims to answer are: * How consistent are the scan results (TUVs) when the scans are repeated over time? * What are normal TUVs in healthy people? This will help define abnormally high values in people with RA. * Are TUVs calculated early after a person starts a new drug to treat RA able to predict whether that person will have a good response to the drug later on (after it has had time to take full effect several weeks later)?

Conditions

  • Rheumatoid Arthritis

Interventions

  • Tc 99m tilmanoceptDrug

    Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arms 1 & 2: Assess Camera-specific Precision of TUVTime frame: Day 0 tilmanocept injection followed by imaging at 60 minutes (60A) and 75 minutes (60B) and at 180 minutes (180A) and 195 minutes (180B).
  2. Arms 1 and 2: Stability of the Mean/Variance RelationshipTime frame: Day 0 tilmanocept injection followed by imaging at 60 minutes and 180 minutes.
  3. Arm 3: Correlation of ΔTUVglobal[5w] and Response to TherapyTime frame: Imaging (60 minutes after tilmanocept injection) on Day 0 and at 5 weeks after new therapy initiation; Assessment of CDAI and ACR Response Criteria at 12 and 24 weeks after new therapy initiation.
  4. Longitudinal (8-day) Variation of TUVTime frame: Imaging (60 minutes after tilmanocept injection) on Day 0 and Day 8

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Imaging Endpoints

    Scottsdale, Arizona

  • Axis Clinical Trials

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • Innovation Medical Research Center

    Palmetto Bay, Florida

  • Physician Research Collaboration

    Lincoln, Nebraska

  • University Hospitals

    Cleveland, Ohio

  • Kettering Medical Center

    Kettering, Ohio

  • Central States Research

    Tulsa, Oklahoma

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.